Medical Communications

Moderna have published antibody persistence data out to six months following the second dose of its COVID-19 vaccine (mRNA-1273) in …

Results from Eli Lily and Incyte’s Phase III study, COV-BARRIER, evaluating baricitinib in the treatment of hospitalised COVID-19 patients did …

Abbott have received CE Mark approval for its next-generation TriClip Transcatheter Tricuspid Valve Repair System, the first-of-its-kind tricuspid heart valve …

Intravac have announced the appointment of Nathalie Laarakker as its new CFO and member of the company’s executive management team. …

Nikki Lucas has been appointed Principal Project Manager within Smithers’ Medical Device Physical Testing team. Lucas has over a decade …

Nordic Nanovector have appointed Peter Braun as their new Chief Executive Officer. Braun is an experienced and entrepreneurial pharmaceutical leader, …

Cardiovascular technology company Ceryx Medical have appointed Chas Taylor as their new chairman. The appointment comes at an interesting time …

In the last week, a number of new developments have made the news; for COVID-19, Starpharma will begin to sell …

The FDA have approved a new indication for Astellas Pharma’s Myrbetriq and Myrbetriq Granules to treat neurogenic detrusor overactivity (NDO), …

Astellas Pharma and Seagen Inc. have announced that the EMA has accepted their marketing authorisation application (MAA) for enfortumab vedotin, …

Novavax is delaying the signing of a contract to supply COVID-19 vaccines to the EU, as the company warned it …

Pfizer have begun testing its COVID-19 vaccine on children under the age of 12, with the trials’ first participants, a …

In the last week, a number of new developments have made the news; for COVID-19, the Oxford-AstraZeneca vaccine has been …

The Russian Direct Investment Fund (RDIF) and Stelis Biopharma have today announced a partnership which aims to produce and supply …

A new second line triple therapy is to be offered to NHS patients in England with multiple myeloma, following a …